retatrutide: The Triple Agonist That Could Redefine Metabolic Medicine (a full clinical breakdown from a clinical GLP-3 RETA - NuRev Peptides

The TRIUMPH 4 study showed that patients with obesity and knee arthritis lost an average of almost 29% of their body weight - an average weight loss of 71 pounds

They may recommend regular monitoring to make sure both medications are working safely and effectively together

March 2026: Novo Nordisk reported top-line REDEFINE-1 Phase 3 CagriSema data showing 22.7% mean body weight reduction at 52 weeks , demonstrating superiority over standalone semaglutide 2.4mg and confirming the semaglutide-plus-amylin combination as clinically competitive with tirzepatide

Mounjaro for weight loss typically costs well over $1,000 per month without insurance, which is why many people look for compounded or discounted options